Review Article

Somatostatin Receptor-Based Molecular Imaging and Therapy for Neuroendocrine Tumors

Ling Wang,1,2,3,4,5 Kun Tang,6 Qi Zhang,2 Huanbin Li,2 Zhengwei Wen,2 Hongzheng Zhang,2 and Hong Zhang1,3,4,5

1 Department of Nuclear Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China
2 Department of Nuclear Medicine, Wenzhou Medical University, Wenzhou, Zhejiang 325003, China
3 Zhejiang University Medical PET Center, Zhejiang University, Hangzhou, Zhejiang 310009, China
4 Institute of Nuclear Medicine and Molecular Imaging, Zhejiang University, Hangzhou, Zhejiang 310009, China
5 Key Laboratory of Medical Molecular Imaging of Zhejiang Province, Hangzhou, Zhejiang 310009, China
6 Department of Radiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China

Correspondence should be addressed to Hong Zhang; hzhang21@gmail.com

Received 17 July 2013; Accepted 8 August 2013

Academic Editor: Mei Tian

Copyright © 2013 Ling Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Neuroendocrine tumors (NETs) are tumors originated from neuroendocrine cells in the body. The localization and the detection of the extent of NETs are important for diagnosis and treatment, which should be individualized according to the tumor type, burden, and symptoms. Molecular imaging of NETs with high sensitivity and specificity is achieved by nuclear medicine method using single photon-emitting and positron-emitting radiopharmaceuticals. Somatostatin receptor imaging (SRI) using SPECT or PET as a whole-body imaging technique has become a crucial part of the management of NETs. The radiotherapy with somatostatin analogues labeled with therapeutic beta emitters, such as lutetium-177 or yttrium-90, has been proved to be an option of therapy for patients with unresectable and metastasized NETs. Molecular imaging can deliver an important message to improve the outcome for patients with NETs by earlier diagnosis, better choice of the therapeutic method, and evaluation of the therapeutic response.

1. Introduction

Neuroendocrine tumors (NETs) are unique tumors that originate almost everywhere in the body from neuroendocrine cells [1]. They have secretory granules which can produce biogenic amines and polypeptide hormones [2]. All these tumors share the features of the neuroendocrine cell system [3]. NETs have particular characteristics including low incidence, low proliferation rate, and sometimes the hyper secretion of biologically active substances [4]. The diagnosis of lesion is limited because it has slow metabolic rate, small size, and various localization [5]. Those NETs of unknown primary may have a relatively favorable prognosis [6]. The primary sites in gastrointestinal and bronchopulmonary tracts are most frequent [7]. Gastroenteropancreatic neuroendocrine (GEP-NET) tumors are neoplasms with variable clinical expressions. They produce and secret various amines and peptides, which can be used as tissue and circulating markers [8], representing approximately 2% of all gastrointestinal tumors [9]. Pheochromocytomas are malignant in approximately 10% of patients. The histology of benign and malignant tumors has no obvious differentiation. The malignant tumors are diagnosed by the presence of metastatic lesions or recurrence [10].

Overall, 5- and 10-year survival rates of NETs were 78 and 63%, respectively [11]. There are various clinical behaviors of NETs. They may have a function or not. The clinical use of specific radiolabeled ligands for imaging and therapy is based on the presence of peptide receptors and transporters at the cell membrane and the neuroamine uptake mechanisms of NETs. Because the majority of NETs express somatostatin receptors (SSTR) which bind to somatostatin (SST), they can be successfully targeted [2]. The understanding and diagnosis of NETs have been greatly improved by morphologic and
Table 1: Characteristics of radionuclides used for SRI and PRRT.

| Radionuclide | Type of decay | Type of rays | Half-life | Energy | Producer |
|--------------|---------------|-------------|-----------|--------|----------|
| $^{111}$In   | EC            | $\gamma$    | 2.8 days  | 173 KeV | $^{111}$Cd (p, n) |
| $^{18}$F     | $\beta^+$     | $\beta$     | 109.8 min | 511 KeV | $^{20}$Ne (d, a) |
| $^{68}$Ga    | $\beta^+$     | $\beta$     | 68.3 min  | 511 KeV | $^{68}$Ge-$^{68}$Ga generator |
| $^{90}$Y     | $\beta^-$     | $\beta$     | 6.7 days  | 2.288 MeV | $^{90}$Sr-$^{90}$Y generator |
| $^{177}$Lu   | $\beta^-$     | $\beta$     | 6.7 days  | 0.5 MeV | $^{176}$Lu (n, $\gamma$) |
| $^{64}$Cu    | $\beta^+$     | $\beta$     | 12.7 h    | 0.653 MeV | $^{64}$Zn (n, p) |

2. SST and SSTR

SST is produced by neuroendocrine, immune, and inflammatory cells in response to many kinds of factors, such as ions, nutrients, neuropeptides, neurotransmitters, and thyroid [13]. It is present in the cerebral cortex, the brain stem, the hypothalamus, the pancreas, and the gastrointestinal tract. It is a cyclic and regulatory peptide consisting of 14 amino acids [13, 14]. A family of G-protein-coupled receptors mediates the function of SST which comprises five distinct subtypes (characterized SSTR1-5) [13, 15]. The SSTR subtypes overexpressed in NETs are related to the type, origin, and grade of differentiation of tumor [16]. A number of different tumors have receptors for SST [17]. SST expresses in various regions such as the brain, the adrenals, the pancreas, and the gastrointestinal tract [18]. SSTR also distributes in tumor tissues of neuroendocrine origin. SSTR is overexpressed in various human cancers. The overexpression of SSTR is a characteristic of NETs, which can be used to localize the primary tumor and its metastases by imaging with the radiolabeled SST analogues [19]. Receptor targeting with subtype-specific radiolabeled SST analogues is based on the structural differences between SSTR subtypes. The imaging of the SST subtype 2 (SST$_2$) overexpressing NETs has been developed and has had extensive clinical applications for almost two decades [20].

There is significant variation in SSTR subtype expression between the tumors of the same type [21]. The majority of tumors expressed SSTR types 1, 2, 3, and 5, and a minority expressed SSTR4 [22]. The expression of SSTR2 on pancreatic endocrine or carcinoid tumors is predominant [21]. The clinical use of SST is limited because it has a short half-life (about 2 minutes) in plasma [23]. SST analogues used to evaluate the use and effectiveness of the management in NETs patients have been synthesized widely. The radioisotopes used in nuclear medicine both for imaging and therapy are shown in Table 1. Imaging with SST analogues is considered as imaging method of first choice for NETs because it has high specificity, low antigenicity, rapid clearance, and good tissue penetration [24]. Octreotide and octreotate are widely used as SST analogues, and the role of SST analogues in the clinical use is well established. This review summarizes the clinical use of SSTR imaging and therapy in NETs as well as the use of SSTR as a platform for gene report imaging.

3. The Clinical Use of Radioisotope Labeled SSTR in NETs

3.1. Somatostatin Receptor Imaging (SRI). SRI is widely used for the diagnosis, as well as staging and restaging of NETs [25]. NETs are usually diagnosed by a combination of clinical symptoms, histology, and hormonal excess. After diagnosis of NET is established, a search for its localization is carried out using common morphologic imaging methods in the past [26]. However, it is difficult to use conventional imaging techniques to map the lesions accurately. There is an urgent need to establish better imaging modalities to detect the lesions for NETs. The tracers used for SPECT and PET in NETs are shown in Table 2.

Table 2: The tracer used for SPECT and PET in NETs and for gene imaging.

| Types of imaging | Radiotracer            |
|------------------|------------------------|
| SPECT            | $^{111}$In-pentetreotide | $^{111}$In-DTPAOC  |
|                  | $^{123}$I-octreotide   | $^{123}$I-octreotide |
|                  | $^{111}$In-DOTA-lanreotide | $^{111}$In-DOTA-NOC-ATE  |
|                  | $^{111}$In-DOTA-BOC-ATE | $^{111}$In-DOTA-BOC-ATE  |
| PET              | $^{68}$Ga-DOTATATE     | $^{68}$Ga-DOTATOC  |
|                  | $^{68}$Ga-DOTANOC      | $^{68}$Ga-DOTANOC  |
|                  | $^{64}$Cu-DOTATATE     | $^{64}$Cu-DOTATATE  |
|                  | $^{18}$F-FP-Gluc-TOCA  | $^{18}$F-FP-Gluc-TOCA  |
| Gene imaging     | $^{94m}$Tc-Demotate 1  | $^{99m}$Tc-P2045  |
|                  | $^{99m}$Tc-P829        | $^{99m}$Tc-P829  |
3.2. Single Photon Emission Computed Tomography (SPECT) Imaging. \(^{111}\)In-pentetreotide used to be the first choice for the visualization of receptor for SST analogues. Tumors and metastases that express the SSTR subtypes SSTR2, SSTR3, or SSTR5 can also be visualized in vivo after injection of \(^{111}\)In-pentetreotide [27]. It differentiates scar tissue from tumor recurrence after the pituitary surgery or radiotherapy. Another agent, \(^{111}\)In-DTPA(0)octreotide (\(^{111}\)In-DTPAOC), is also a tracer of a great potential use for the imaging of SSTR-positive tumors. \(^{111}\)In-DTPAOC scintigraphy is also a scintigraphy modality of choice for NETs. Still, there are patients in whom imaging findings are negative or weak positive [28]. \(^{111}\)In-DOTATOC is reported to be of great value for the visualization of patients with octreotide receptor-positive tumors [29]. The efficacy of scanning with \(^{125}\)I-octreotide was evaluated by localizing tumors in 42 patients with NETs. It was found that those often unrecognized primary tumors or metastases were visualized in 12 of 13 patients with carcinoid tumors as well as in 7 of 9 patients with endocrine pancreatic tumors.

There is an overall high sensitivity of SRI to localize NETs. The value of SRI in patients with NETs has been proven [17, 30, 31]. The scintigraphy provides important information in NET patients and has a strong impact on further therapeutic management [31]. Both positive and negative results of SRI are very useful; the former may predict the effect of octreotide therapy to NETs [17].

3.3. Positron Emission Tomography (PET) Imaging. \(^{68}\)Ga-labeled somatostatin analogues are widely used [2]. The two compounds frequently used in functional PET imaging are \(^{68}\)Ga-DOTA (0), Tyr (3) octreotate (\(^{68}\)Ga-DOTATATE) and \(^{68}\)Ga-DOTATOC [32]. \(^{68}\)Ga-DOTATOC PET/CT is a useful imaging modality for NETs. In 38 patients, the sensitivity is 82% [33]. Another study of 18 patients with pulmonary NETs showed that all typical carcinoids showed a high uptake of \(^{68}\)Ga-DOTATATE [34]. The comparison of the \(^{111}\)In-DTPAOC SPECT and \(^{68}\)Ga-DOTATOC PET shows that the latter is superior in detecting small lesions with low tracer uptake [35]. In another comparison study of 84 patients with known or suspected NETs, \(^{68}\)Ga-DOTATOC PET shows a significantly higher detection rate compared with SPECT and diagnostic CT [36]. A study of 40 patients with metastatic NETs who underwent \(^{68}\)Ga-DOTATOC and \(^{68}\)Ga-DOTATATE PET/CT reported that the two had almost the same accuracy for the diagnosis of NET lesions; however, standard uptake value (SUV) max of \(^{68}\)Ga-DOTATOC scans is higher than \(^{68}\)Ga-DOTATATE (Figure 1) [32]. It was also reported that the diagnostic value of PET/CT with \(^{68}\)Ga-DOTATOC and \(^{68}\)Ga-DOTATOC in the same patients with GEP-NET is almost the same, but the maximal uptake of \(^{68}\)Ga-DOTATOE tended to be higher than \(^{68}\)Ga-DOTATOC [37].

A case reported that, in a patient who had synchronous colorectal cancer and pancreatic NET, the \(^{68}\)Ga-DOTATATE PET and \(^{18}\)F-FDG PET imaging showed two different tumor types within the liver metastases. This case suggested that combinational \(^{68}\)Ga-DOTATATE PET and \(^{18}\)F-FDG PET imaging modalities are of potential use in understanding the biology of the NETs and managing the NETs [38].

Several novel agents have been developed. DOTANOC is the first compound for PET imaging and is reported to have a higher affinity for SSTR2 as well as for SSTR5 [39]. The first in-humans study with \(^{64}\)Cu-DOTATATE imaging
had an excellent imaging quality, reduced radiation burden, and increased lesion detection rate when compared with \(^{111}\)In-DTPA-octreotide. It identified additional lesions in 6 of 14 patients (43%) [40]. \(^{18}\)F-fluoropropionyl-Lys0-Tyr3-octreotate (\(^{18}\)F-FP-Gluc-TOCA), another new carbohydrate analog of octreotide, is under research [41]. In 25 patients with different SSTR-positive tumors, \(^{18}\)F-FP-Gluc-TOCA showed a fast and intense tumor accumulation and a rapid clearance from blood serum [42].

A study concluded the sensitivity and specificity of SSTR PET or PET/CT in detecting thoracic and/or GEP-NETs, which were 93% and 91%, respectively [43]. PET resulted in a modified restage in 12 patients (28.6%), while the treatment plans were affected in 32 patients (76.2%). It prevented unnecessary surgery in six patients, while two patients with lesions that did not express SSTR were excluded from PRRT [44]. \(^{68}\)Ga-DOTANOC PET/CT can affect the tumor staging and modify the treatment in more than half the patients [19]. To predict the therapy response earlier in tumors is essential to guide the therapy and at the same time avoid the side effects and lower the costs caused by ineffective therapies [45]. However, using conventional imaging techniques and response criteria to assess treatment response is often complicated [12]. Decreased \(^{68}\)Ga-DOTATE uptake in lesions after the first cycle of PRRT correlated with clinical symptoms improvement and predicted time to progression in well-differentiated NET patients [45].

3.4. Somatostatin Receptor Targeted Radionuclide Therapy (SRTRT). The treatment of the NETs includes peptide receptor therapy, somatostatin analogues, and surgery [28]. Surgery is still the therapy of first choice, while the vast majority of NETs will need further treatment with SST analogues and/or interferon [46]. There are few treatment options for those metastasized or inoperable endocrine GEP tumors. Chemotherapy for those NETs may be effective, but the response usually lasts less than one year [47]. The predominant expression of SST\(_2\) receptors in NETs is essential for the application of radiolabeled octapeptide SST analogues [21], as well as for PRRT using \(^{90}\)Y- and \(^{177}\)Lu-DOTATATE/DOTATOC [48]. The radiological response was measured with response evaluation criteria in solid tumors (RECIST) criteria [49]. SSTR PET imaging, including the common tracer \(^{68}\)Ga-DOTATOC, is becoming the basis of the selection of candidates for PRRT [50]. Patients with high \(^{68}\)Ga-DOTATOC uptake (SUV > 5.0) were recommended to \(^{90}\)Y-DOTATOC therapy [51, 52]. For those NETs that demonstrate uptake in scintigraphy with \(^{111}\)In-octreotide, the therapy with \(^{111}\)In/\(^{90}\)Y-octreotide is a modality [46].

\(^{90}\)Y-DOTATOC is a potential choice which can deliver high absorbed doses to tumors expressing SST\(_2\) receptors, and the therapeutic response is achieved in about 25% of patients [23]. High-dose \(^{90}\)Y-DOTATOC targeted radiotherapy is a well-tolerated treatment which has significant clinical benefit and objective response for NETs [53]. A phase 2 study included 38 patients with advanced stage well-differentiated NETs treated with a fixed \(^{90}\)Y-DOTATOC dose of 2.56 GBq bimonthly showed that 43.6% patients had a partial response (PR), 25.6% had stable disease (SD), and 28.2% had progressive disease (PD) and that the median progression-free survival (PFS) was 22.3 months. The treatment of metastatic NETs with fixed activity is reported useful and safe [54].

Antitumor effects of \(^{90}\)Y-DOTATOC have been reported considerably different between various studies [55]. A review revealed that the objective response rates are in the range from 20% to 28% for all NETs with \(^{90}\)Y-DOTATOC therapy. In patients with GEP-NET, the response rate was in the range from 28% to 38%. Overall, the cumulative response rate was 24% [56]. The objective responses were 5 PR, 7 minor responses, 29 SD, and 17 PD in a phase 1 dose-escalating treated study of \(^{90}\)Y-DOTATOC in 58 patients with SSTR-positive GEP-NET. Furthermore, there is a significantly longer overall survival (OS) compared with historic controls [57]. In metastatic NET patients, the result was complete response (CR) 4%, PR 23%, SD 62% in 116 patients, and PD 11%, and \(^{90}\)Y-DOTATOC also induced a better outcome [58]. Sowa-Staszczak et al. reported that \(^{90}\)Y-DOTATOC therapy results in symptomatic relief and tumor mass reduction in NETs. The response was 47% SD, 31% PR, and 9% PD, and the PFS was 37.4 months [59]. Clinical PR at six months was in 43 of 60 (72%) patients with histologically proven GEP-NETs after \(^{90}\)Y-DOTATATE treatment, and 9 patients had SD, and PD was noted in 8 patients. PFS was 17 months, and the OS was 22 months [49].

\(^{177}\)Lu-DOTATATE, another radiopharmaceutical for treatment purpose, was used in GEP-NET patients. It was reported that CR and PR occurred in 2% and 28% of patients, respectively, and minor tumor response occurred in 16%. There was a 40 to 72 months survival benefit from diagnosis when compared with historical controls [60]. Treatment results with \(^{177}\)Lu-octreotide are preferable in patients with a limited lesion. Even in patients with no PD, early treatment may be better [47]. In the same patients, same dosage (3,700 MBq) of \(^{177}\)Lu-DOTATOC and \(^{177}\)Lu-DOTATATE was administered in different stages of treatment to see which should be preferred for PRRT. It indicated that the \(^{177}\)Lu-DOTATATE residence time of tumor was longer than \(^{177}\)Lu-DOTATOC [61]. This therapy is available, safe, and effective and has no serious adverse events [62]. \(^{177}\)Lu-DOTATATE is efficacious on small lesions when compared with \(^{90}\)Y-DOTATOC, which seems to be more efficient in bigger lesions [23, 63]; however, fractionated therapy with \(^{177}\)Lu-DOTATATE should be considered as a treatment option also for those patients with large tumors, high proliferation, and high receptor expression [64]. Studies with \(^{177}\)Lu-DOTATATE indicate that more cycles of such therapy are still safe. The median PFS is longer than 40 months [65]. The quality of life of those patients was improved remarkably after the therapy. Kwekkeboom et al. advocated \(^{177}\)Lu-octreotide therapy in patients with GEP tumors not waiting for tumor progression because of the high success rate and the absence of serious side effects (Figure 2) [66].

With \(^{177}\)Lu-DOTATATE treatments, tumor regression of 50% or more was achieved in 28% of patients. In 19% of patients, tumor regression was in 25% to 50%, SD showed in 35%, and PD showed in 18% of patients [55].
Figure 2: (a)–(c) Planar scans of the abdomen, 3 days after the injection of 200 mCi $^{177}$Lu-octreotate in a patient with liver metastases of an operated neuroendocrine pancreatic tumor. (a) After the first treatment; (b) after the second treatment; (c) after the fourth treatment. Note the loss of intensity of uptake in the liver lesions (arrows in (a)). This sign virtually always indicates a tumor volume response. (d) and (e). CT scans of the same patient: (d) before treatment; (e) 3 months after the last treatment. Tumor (arrows in (d)) is not demonstrated on (e). Neither MRI nor octreoscan could demonstrate definite tumor deposits at that time [66].

of life is improved remarkably after treatment with $^{177}$Lu-DOTATATE [55, 67]. The combination of $^{177}$Lu-octreotate and capcitabine treatment was safe and feasible and may enhance these antitumor effects [68]. The study including 50 patients with metastasized NETs which compared combined $^{90}$Y/$^{177}$Lu-DOTATATE therapy with single $^{68}$Ga-DOTATATE showed that tandem radioisotopes therapy gives longer OS than a single one [69].

Oh et al. evaluated the effect of PRRT on the glucose metabolism and SSTR density assessed by $^{18}$F-FDG PET/CT and $^{68}$Ga-DOTANOC PET/CT, respectively. Only 56% (77/138) of the lesions show matched SSTR expression and glucose metabolism; the relationship is complicated [48]. In another study, the number of tumor lesions identified on $^{177}$Lu-DOTATATE scans during PRRT for dosage purpose was compared to those detected on $^{68}$Ga-DOTATATE studies obtained before the therapy; 318 lesions were detected in a total of 44 patients, while 280 (88%) lesions were concordant. Among those discordant lesions, 29 were $^{68}$Ga-DOTATATE positive and $^{177}$Lu-DOTATATE negative, whereas 9 were $^{68}$Ga-DOTATATE negative and $^{177}$Lu-DOTATATE positive. The sensitivity, accuracy, and positive predictive value for $^{177}$Lu-DOTA-TATE were 91%, 88%, and 97%, respectively, as compared to $^{68}$Ga-DOTATATE [70].

Radiolabeled octreotide analogues therapy is effective in patients with NETs [71], especially for GEP tumors [63]. The repeated cycles of PRRT enabled stabilization of the disease and did not cause an obvious toxicity increase of PRRT. Radiolabeled receptor-binding SSTR analogues (octreotide and lanreotide) target radioactivity to tissues expressing SSTRs which can be used for the management of NETs [63]. Side effects are described, and information on SST analog treatment is provided [72]. It is suggested that the octreotide PRRT is better when compared to octreotide in reducing diarrhea and flushing [61]. We summarize the studies that evaluate the PRRT efficacy in NETs in Table 3.

Dose-limiting factors for PRRT are kidney and/or bone marrow dose [61]. The uptake of $^{68}$Ga-DOTATOC was low in almost all organs except the kidneys [73]. The amount of radioactivity that can be used safely depends on the radiation dose to the kidneys [71]. The range of particles from $^{90}$Y is maximally 12 mm, which is long enough to reach the glomeruli; however, the range of the $^{177}$Lu electrons is shorter, maximally 2.1 mm, which causes much lower average decline
in creatinine clearance in the latter patients than in the former patients [71]. The dose-limiting toxicity of $^{90}$Y-DOTATOC is renal insufficiency, starting at dose of 7.4 GBq/m² [74]. However, the kidney and blood morphology parameters changes were transient [75]. When kidney protective agents are used, the side effects are few and mild [76]. PRRT therapy might become the first-line therapy in patients with disseminated or inoperable GEP-NETs [55]. The predictive factors for tumor remission include high tumor uptake on SRI and limited amount of liver metastases.

4. Somatostatin Receptor Based Reporter Gene Imaging

The human SSTR subtype 2 (hSSTr2), as a reporter gene, is under research for molecular imaging applications which have several features for potential translation to human studies [73, 77]. In vitro and in vivo studies have been done for this reporter system [73]. There are two approved SST analogues used for the expression of the reporter gene imaging [77]. SSTr2 is used as a reporter probe for imaging SST analogues used for the expression of the reporter gene [83]. Gene transfer technology can improve the degree and specificity of radiolabeled peptide localization in tumors [84]. The hSSTr2 was monitored as a reporter gene for $^{99m}$Tc-P2045 (an SST analogue) imaging showed adenoviral gene transfer to cancers, such as ovarian cancer [85]. This is a noninvasive imaging method for imaging gene transfer to ovarian cancer, which is helpful for planning a human gene therapy trial.

5. Discussion

Significant advances have been made in the imaging of NETs, but the challenge is to find the ideal imaging method with increased sensitivity and better tomographic localization of the primary and metastatic disease [86]. SRS is an ideal modality for evaluating NETs patients, which is not affected by their proliferative activity. Furthermore, when those patients have negative results on SRS, FDG PET should be used [87]. Both SPECT and PET can be very helpful in diagnosing NETs; however, PET may give more accurate information about the primary and metastatic lesions of NETs. PET or PET/CT is recommended as a first-line diagnostic imaging technology in patients with suspicious NETs [43]. The in vitro affinity of $^{68}$Ga-DOTATATE binding with the SST₂ is higher than that of $^{68}$Ga-DOTATOC. However, the uptake value of the latter is higher than the former. The $^{68}$Ga-DOTATATE uptake and the histologic grade of NETs were not correlated [28]. Functional imaging with both $^{68}$Ga-DOTATATE and $^{18}$F-FDG is of potential use for a more comprehensive tumor assessment in intermediate-grade and high-grade tumors [33]. $^{68}$Ga-DOTATOC uptake in the head of the pancreas is commonly found in patients

### Table 3: The radioagent used in PRRT and the efficacy of the therapy.

| Therapeutic agents | Subjects | Dosage               | Duration | Main findings                        | References |
|--------------------|----------|----------------------|----------|--------------------------------------|------------|
| $^{90}$Y-DOTATATE  | 46 NETs  | 7.4 GBq/m²           | 3–5 cycles | PFS 37.4 months                     | [59]       |
| $^{90}$Y-DOTATOC  | 116 Metastatic NETs | 162–200 mCi/m²   | 2–4 cycles | Significant reduction of symptoms was found in 83% of patients | [58]       |
| $^{177}$Lu-DOTATATE | 310 GEP-NETs | 750 to 800 mCi | 4 cycles | Survival benefit of 40 to 72 months from diagnosis | [60]       |
| $^{177}$Lu-DOTATOC | 27 relapse NETs | 7,400 MBq     | Once     | 2 PR, 5 MR, 12 SD, and 8 PD         | [62]       |
undergoing \(^{68}\text{Ga-DOTATOC}\) PET/CT. Therefore, quantification should be used to avoid false-positive diagnosis [88]. Furthermore, neither \(^{111}\text{In-DTPAOC SPECT}\) nor \(^{68}\text{Ga-DOTATOC}\) PET imaging was sensitive in the detection of liver metastases since they showed a lower uptake than the surrounding normal liver tissue compared to CT [35]. Recently, a new \(^{111}\text{C-5-HTP-PET}\) has been reported that is sensitive in small NET lesions imaging and can image more tumor lesions than SRI and CT [89]. Moreover, scintigraphy of the upper abdomen is affected by breathing artifacts, so misalignment due to respiratory motions must be considered [88].

Despite the fact that most GEP-NETs are slow growing, OS in NET patients with liver metastases is 2 to 4 years. In metastatic cases, there are limits of cytoreductive therapeutic options [60]. PRRT is a promising new method in the treatment of patients with inoperable or metastasized NETs because of its fewer side effects and less toxicity and better curative effect [86]. Individual dosimetry seems helpful for deciding whether a patient can be chosen for radiolabeled DOTATOC or DOTATATE therapy or not and deciding the therapeutic modality for each patient [32]. Evaluation of NETs therapy response is difficult; for assessing such response, the monitoring of functional parameters is more accurate than morphologic measurements [45]. A positive scintigram suggests good response to treatment with octreotide in many cases [19]. The foundation of the dose-response relationship and the decision of the correct dose of PRRT are important to achieve an ideal treatment [56].

Beta particles with higher energies and longer range emitted by \(^{90}\text{Y}\) may be preferable for larger tumors, while \(^{177}\text{Lu}\) that emits beta particles with shorter range and longer half-life may be a good choice for small tumors. In patients with tumors of nonhomogeneous receptor distribution and various sizes, a combination of radionuclide might be useful [69]. \(^{90}\text{Y-DOTATOC}\) therapy has proven to be an effective and safe treatment. Before and after the therapy, blood tests for kidney, liver function, and chromogranin A were performed. During 12 months followup, transient decrease of PLT, WBC, and hemoglobin values and GFR values were found [59]. The mild critical organ toxicity does not limit the PRRT of NETs [59]. Standard dosages of \(^{68}\text{Ga-DOTATATE}\) result in a relatively low risk of myelotoxicity. However, because of risk of renal toxicity, the kidneys should be monitored carefully [49]. The further goal is to further reduce renal toxicity so that higher doses can be administered [53].

\(^{68}\text{Ga-DOTATOC}\) is a specific ligand for hSST2 reporter system and so that for hSST2 reporter gene PET imaging. Because DOTATOC has been tested clinically, this reporter system can be used for translation to human studies [73]. The relative level of gene expression for SST2 was positively related to patient outcome in the childhood neuroblastoma tumor and neuroblastoma tumor. Imaging with \(^{111}\text{In-pentetreotide}\) may have not only a diagnostic but also a prognostic value [80]. There is great use of \(^{99m}\text{Tc}\)-labeled peptides for imaging gene transfer with the hSST2 reporter receptor, specifically when the reporter correlates with the expression of therapeutic genes [83]. Selective internal radiation therapy (SIRT) is a well tolerated and effective treatment for unresectable NET with liver metastases [90].

### 6. Perspective

The SSTR-based molecular imaging is a noninvasive and quantitative method to diagnose the NETs and evaluate the therapeutic efficacy for NETs. The development of radiolabeled SST analogues has affected the clinical management of patients with NETs. PET/CT can be useful in the early prediction of the treatment outcome of NET patients who underwent PRRT. Furthermore, the clinical management of NETs will be further improved if better radioligands are developed and more technologies are used to identify the radiotherapy treatment response in patients with NETs.

Dual therapy is a promising method to treat NETs. The combination of PRRT and EBRT can increase the dose delivered to the tumor and reduce the dose for organs at risk. The clinical use of molecular imaging is not only in diagnosis and treatment efficacy evaluation, but also in patient selection. Still, it plays an important role in the reporter gene research. Personalized diagnosis and treatment of NETs will be established based on increased understanding of molecular mechanisms of NETs.

### Abbreviations

- **NETs**: Neuroendocrine tumors
- **GEP**: Gastroenteropancreas
- **SSTR**: Somatostatin receptors
- **SST**: Somatostatin
- **SST2**: Sst subtype 2
- **SRI**: Somatostatin receptor imaging
- **PET**: Positron emission tomography
- **SRS**: Somatostatin receptors scintigraphy
- **CT**: Computed tomography
- **PRRT**: Peptide receptor radionuclide therapy
- **SUV**: Standard uptake value
- **AAV**: Adeno-associated viral
- **SIRT**: Selective internal radiation therapy
- **RECIST**: Response evaluation criteria in solid tumors
- **PR**: Partial response
- **SD**: Stable disease
- **PD**: Progressive disease
- **PFS**: Progression-free survival
- **OS**: Overall survival
- **CR**: Complete response
- **hSST2**: Human somatostatin receptor subtype 2
Conflict of Interests
The authors declare that they have no conflict of interests.

Acknowledgments
This work is partly sponsored by Grants from the Zhejiang Provincial Natural Science Foundation of China (Z2110230), Health Bureau of Zhejiang Province (2011ZDA013), and National Science Foundation of China (NSFC) (no. 30672396). This work was reprinted by permission of SNMMI from Poeppel et al. [32].

References
[1] K. P. Koopmans, O. N. Neels, I. P. Kema et al., “Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results,” Critical Reviews in Oncology/Hematology, vol. 71, no. 3, pp. 199–213, 2009.
[2] V. Rufini, M. L. Calcagni, and R. P. Baum, “Imaging of neuroendocrine tumors,” Seminars in Nuclear Medicine, vol. 36, no. 3, pp. 228–247, 2006.
[3] C. Capella, P. U. Heirz, H. Hofer, E. Solcia, and G. Kloppel, “Revised classification of neuroendocrine tumours of the lung, pancreas and gut,” Virchows Archiv, vol. 425, no. 6, pp. 547–560, 1995.
[4] E. Bombardieri, M. Maccuro, E. De Deckere, G. Savelli, and A. Chiti, “Nuclear medicine imaging of neuroendocrine tumours,” Annals of Oncology, vol. 12, supplement 2, pp. S51–S61, 2001.
[5] V. Ambrosini, D. Campana, P. Tomassetti, G. Grassetto, D. Rubello, and S. Fantin, “PET/CT with 68 Gallium-DOTA-peptides in NET: an overview,” European Journal of Radiology, vol. 80, no. 2, pp. e116–e119, 2011.
[6] A. Stoyianni, G. Pentheroudakis, and N. Pavlidis, “Neuroendocrine carcinoma of unknown primary: a systematic review of the literature and a comparative study with other neuroendocrine tumors,” Cancer Treatment Reviews, vol. 37, no. 5, pp. 358–365, 2011.
[7] I. M. Modlin, K. D. Lye, and M. Kidd, “A 5-decade analysis of 13,715 carcinoid tumors,” Cancer, vol. 97, no. 4, pp. 934–959, 2003.
[8] D. P. Lindholm and K. Oberg, “Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors,” Hormone and Metabolic Research, vol. 43, no. 12, pp. 832–837, 2011.
[9] K. Oberg, “Biology, diagnosis, and treatment of neuroendocrine tumors of the gastrointestinal tract,” Current Opinion in Oncology, vol. 6, no. 4, pp. 441–451, 1994.
[10] V. E. Strong, T. Kennedy, H. Al-Ahmadi et al., “Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis,” Surgery, vol. 143, no. 6, pp. 759–768, 2008.
[11] U.-F. Pape, U. Berndt, J. Müller-Nordhorn et al., “Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumors,” Endocrine-Related Cancer, vol. 15, no. 4, pp. 1083–1097, 2008.
[12] A. Sundin and A. Rockall, “Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: the challenges ahead,” Neuroendocrinology, vol. 96, no. 4, pp. 261–271, 2012.
[13] Y. C. Patel, “Somatostatin and its receptor family,” Frontiers in Neuroendocrinology, vol. 20, no. 3, pp. 157–198, 1999.
[14] P. Brazeau, J. Epelbaum, and G. S. Tannenbaum, “Somatostatin: isolation, characterization, distribution, and blood determination,” Metabolism, vol. 27, no. 9, pp. 1133–1137, 1978.
[15] D. Hoyer, G. I. Bell, M. Berelowitz et al., “Classification and nomenclature of somatostatin receptors,” Trends in Pharmacological Sciences, vol. 16, no. 3, pp. 86–88, 1995.
[16] J. C. Reubi, B. Waser, J.-C. Schaer, and J. A. Lissau, “Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands,” European Journal of Nuclear Medicine, vol. 28, no. 7, pp. 836–846, 2001.
[17] S. W. J. Lamberts, W. H. Bakker, J.-C. Reubi, and E. P. Kren- ning, “Somatostatin-receptor imaging in the localization of endocrine tumors,” The New England Journal of Medicine, vol. 323, no. 18, pp. 1246–1249, 1990.
[18] J. C. Reubi, L. Kvols, E. Krenning, and S. W. J. Lamberts, “Distribution of somatostatin receptors in normal and tumor tissue,” Metabolism, vol. 39, no. 9, pp. 78–81, 1990.
[19] E. P. Krenning, D. J. Kwekkeboom, W. H. Bakker et al., “Somato- statin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr1]-octreotide: the Rotterdam experience with more than 1000 patients,” European Journal of Nuclear Medicine, vol. 20, no. 8, pp. 716–731, 1993.
[20] J. C. Reubi and H. R. Maecke, “Peptide-based probes for cancer imaging,” Journal of Nuclear Medicine, vol. 49, no. 11, pp. 1735–1738, 2008.
[21] W. W. de Herder, L. J. Hofland, A. J. Van Der Lely, and S. W. J. Lamberts, “Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours,” Endocrine-Related Cancer, vol. 10, no. 4, pp. 451–458, 2003.
[22] M. Papotti, M. Bongiovanni, M. Volante et al., “Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors: a cumulative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis,” Virchows Archiv, vol. 440, no. 5, pp. 461–475, 2002.
[23] L. Bodei, M. Cremonesi, C. Grana et al., “Receptor radionuclide therapy with 90Y-[DOTATOC]-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 31, no. 7, pp. 1038–1046, 2004.
[24] A. Al-Nahhas, Z. Win, T. Szyszko et al., “Gallium–68 PET: a new frontier in receptor cancer imaging,” Anticancer Research, vol. 27, no. 6 B, pp. 4087–4094, 2007.
[25] K. K. Wong, R. T. Waterfield, M. C. Marzola et al., “Contem- porary nuclear medicine imaging of neuroendocrine tumours,” Clinical Radiology, vol. 67, no. 11, pp. 1035–1050, 2012.
[26] N. Naswa and C. S. Bal, “Divergent role of 68Ga-labeled somato- statin analogs in the workup of patients with NETs: AIIMS experience,” Recent Results in Cancer Research, vol. 194, pp. 321–351, 2012.
[27] W. W. de Herder, D. J. Kwekkeboom, R. A. Feelders et al., “Somatostatin receptor imaging for neuroendocrine tumors,” Pituitary, vol. 9, no. 3, pp. 243–248, 2006.
[28] R. Srirajaskanthan, I. Kayani, A. M. Quigley, J. Soh, M. E. Cap- lin, and J. Bomanji, “The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy,” Journal of Nuclear Medicine, vol. 51, no. 6, pp. 875–882, 2010.
[29] M. De Jong, W. H. Bakker, E. P. Krenning et al., “Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA6, D-Phe1, Tyr1]octreotide, a promising somatostatin
analogue for radionuclide therapy,” *European Journal of Nuclear Medicine*, vol. 24, no. 4, pp. 368–371, 1997.

[30] D. J. Kwekkeboom and E. P. Krenning, “Somatostatin receptor imaging,” *Seminars in Nuclear Medicine*, vol. 32, no. 2, pp. 84–91, 2002.

[31] M. Schmidt, E. Fischer, M. Dietlein et al., “Clinical value of somatostatin receptor imaging in patients with suspected head and neck parangliomas,” *European Journal of Nuclear Medicine*, vol. 29, no. 12, pp. 1571–1580, 2002.

[32] T. D. Poeppel, I. Binse, S. Petersenn et al., “68Ga-DOTATOC versus 66Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors,” *Journal of Nuclear Medicine*, vol. 52, no. 12, pp. 1864–1870, 2011.

[33] I. Kayani, J. B. Bomanji, A. Groves et al., “Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (Dota-DPhe1,Tyr3)-octreotate and 18F-FDG,” *Cancer*, vol. 112, no. 11, pp. 2447–2455, 2008.

[34] I. Kayani, B. G. Conry, A. M. Groves et al., “A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors,” *Journal of Nuclear Medicine*, vol. 50, no. 12, pp. 1927–1932, 2009.

[35] J. Kowalski, M. Henze, J. Schuhmacher, H. R. Mäcke, M. Hofmann, and U. Haberkorn, “Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D-Phe1-Tyr3-octreotide in comparison to [111In]-DTPA-TOCPECT. First results in patients with neuroendocrine tumors,” *Molecular Imaging and Biology*, vol. 5, no. 1, pp. 42–48, 2003.

[36] M. Gabriel, C. Decristoforo, D. Kendler et al., 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT,” *Journal of Nuclear Medicine*, vol. 48, no. 4, pp. 508–518, 2007.

[37] T. D. Poeppel, I. Binse, S. Petersen et al., 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors,” *Journal of Nuclear Medicine*, vol. 52, no. 12, pp. 1864–1870, 2011.

[38] K. Desai, J. Watkins, N. Woodward et al., “Use of molecular imaging to differentiate liver metastasis of colorectal cancer metastasis from neuroendocrine tumor origin,” *Journal of Clinical Gastroenterology*, vol. 45, no. 1, pp. e8–e11, 2011.

[39] D. Wild, H. R. Mäcke, B. Waser et al., 68Ga-DOTATOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5,” *European Journal of Nuclear Medicine and Molecular Imaging*, vol. 32, no. 6, pp. 724, 2005.

[40] A. Pfeifer, U. Knigge, J. Mortensen et al., “Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study,” *Journal of Nuclear Medicine*, vol. 53, no. 8, pp. 1207–1215, 2012.

[41] H. J. Wester, M. Schottelius, K. Scheidhauer et al., “PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide,” *European Journal of Nuclear Medicine and Molecular Imaging*, vol. 30, no. 1, pp. 117–122, 2003.

[42] G. Meisetschlager, T. Poethko, A. Stah et al., “Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide,” *Journal of Nuclear Medicine*, vol. 47, no. 4, pp. 566–573, 2006.

[43] G. Treglia, P. Castaldi, G. Rindi, A. Giordano, and V. Ruffini, “Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis,” *Endocrine*, vol. 42, pp. 80–87, 2012.

[44] V. Ambrosini, D. Campana, L. Bodei et al., 68Ga-DOTATOC PET/CT clinical impact in patients with neuroendocrine tumors,” *Journal of Nuclear Medicine*, vol. 51, no. 5, pp. 669–673, 2010.

[45] A. R. Haug, C. J. Auernhammer, B. Wängler et al., 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors,” *Journal of Nuclear Medicine*, vol. 51, no. 9, pp. 1349–1356, 2010.

[46] G. Kaltas, A. Rockall, D. Papadogias, R. Reznik, and A. B. Grossman, “Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours,” *European Journal of Endocrinology*, vol. 151, no. 1, pp. 15–27, 2004.

[47] D. J. Kwekkeboom, J. J. Teunissen, W. H. Bakker et al., “Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors,” *Journal of Clinical Oncology*, vol. 23, no. 12, pp. 2754–2762, 2005.

[48] S. Oh, V. Prasad, D. S. Lee, and R. P. Baum, “Effect of peptide receptor radionuclide therapy on somatostatin receptor status and glucose metabolism in neuroendocrine tumors: intranidividual comparison of Ga-68 DOTANOC PET/CT and F-18FDG PET,” *International Journal of Molecular Imaging*, vol. 2011, Article ID 524130, 7 pages, 2011.

[49] J. B. Cwikla, A. Sankowski, N. Seklecka et al., “Efficacy of radionuclide treatment DOTANOC Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study,” *Annals of Oncology*, vol. 21, no. 4, pp. 787–794, 2009.

[50] S. Ezziddin, J. Lohmar, C. J. Yong-Hing et al., “Does the pretherapeutic tumor SUV in 68 Ga DOTATOC PET predict the absorbed dose of 177 Lu octreotate?” *Clinical Nuclear Medicine*, vol. 37, pp. e141–e147, 2012.

[51] S. Koukouri, L. G. Strauss, V. Georgoulia, M. Eisenhut, U. Haberkorn, and A. Dimitrakopoulou-Strauss, “Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy,” *European Journal of Nuclear Medicine and Molecular Imaging*, vol. 33, no. 10, pp. 1115–1122, 2006.

[52] S. Koukouri, L. G. Strauss, V. Georgoulia et al., “Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy,” *European Journal of Nuclear Medicine and Molecular Imaging*, vol. 33, no. 4, pp. 460–466, 2006.

[53] C. Waldherr, M. Pless, H. R. Maecke et al., “Tumor response and clinical benefit in neuroendocrine tumors after 74 Gbq 90Y-DOTATOC,” *Journal of Nuclear Medicine*, vol. 43, no. 5, pp. 610–616, 2002.

[54] G. Savelli, F. Bertagna, F. Franco et al., “Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumours with a fixed activity of 90Y-DOTA-D-Phe1-Tyr3 octreotide,” *Cancer*, vol. 118, pp. 2915–2924, 2012.

[55] M. Van Essen, E. P. Krenning, M. De Jong, R. Valkema, and D. J. Kwekkeboom, “Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours,” *Acta Oncologica*, vol. 46, no. 6, pp. 723–734, 2007.

[56] L. Nisa, G. Savelli, and R. Giubbini, “Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumours: a selected review,” *Annals of Nuclear Medicine*, vol. 25, no. 2, pp. 75–85, 2011.
[57] R. Valkema, S. Pauwels, L. K. Kvols et al., “Survival and response after peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors,” Seminars in Nuclear Medicine, vol. 36, no. 2, pp. 147–156, 2006.

[58] F. Forrer, C. Waldherr, H. R. Macek, and J. Mueller-Brand, “Targeted radionuclide therapy with [90Y-DOTATOC in patients with neuroendocrine tumors,” Anticancer Research, vol. 26, no. 1 B, pp. 703–707, 2006.

[59] A. Sowa-Staszczak, D. Pach, J. Kunikowska et al., “Efficacy and safety of [90Y-DOTATATE therapy in neuroendocrine tumours,” Endokrynologia Polska, vol. 62, no. 5, pp. 392–400, 2011.

[60] D. J. Kwekkeboom, W. W. De Herder, B. L. Kam et al., “Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA,Tyr3]octreotate: toxicity, efficacy, and survival,” Journal of Clinical Oncology, vol. 26, no. 13, pp. 2124–2130, 2008.

[61] J. P. Esser, E. P. Krenning, J. J. M. Teunissen et al., “Comparison of [177 Lu-DOTA,Tyr3]octreotide and [111 In-DOTA,Tyr3]octreotate: which peptide is preferable for PRRT?” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 11, pp. 1346–1351, 2006.

[62] F. Forrer, H. Uusijärvi, D. Storch, H. R. Macek, and J. Mueller-Brand, “Treatment with [177 Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with [177 Y-DOTATOC,” Journal of Nuclear Medicine, vol. 46, no. 8, pp. 1310–1316, 2005.

[63] G. A. Kaltas, D. Papadogias, P. Makras, and A. B. Grossman, “Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues,” Endocrine-Related Cancer, vol. 12, no. 4, pp. 683–699, 2005.

[64] U. Garske, M. Sandstrom, S. Johansson et al., “Lessons on tumour response: imaging during therapy with [177 Lu-DOTA-TATE octreotate. a case report on a patient with a large volume of poorly differentiated neuroendocrine carcinoma,” Theranostics, vol. 2, pp. 459–471, 2012.

[65] B. L. Kam, J. J. Teunissen, E. P. Krenning et al., “Lutetium-labelled peptides for therapy of neuroendocrine tumours,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, supplement 1, pp. S103–S112, 2012.

[66] D. J. Kwekkeboom, W. H. Bakker, B. L. Kam et al., “Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177 Lu-DOTA,Tyr2]octreotate,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 30, no. 3, pp. 417–422, 2003.

[67] D. J. Kwekkeboom, W. W. De Herder, C. H. J. van Eijck et al., “Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors,” Seminars in Nuclear Medicine, vol. 40, no. 2, pp. 78–88, 2010.

[68] M. Van Essen, E. P. Krenning, B. L. Kam, W. W. De Herder, M. O. Van Aken, and D. J. Kwekkeboom, “Report on short-term side effects of treatments with [177 Lu-octreotate in combination with capicitabine in seven patients with gastroenteropancreatic neuroendocrine tumours,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 4, pp. 743–748, 2008.

[69] J. Kunikowska, L. Królcki, A. Hubalewska-Dydejczyk, R. Mikolajczak, A. Sowa-Staszczak, and D. Pawlak, “Clinical results of radionuclide therapy of neuroendocrine tumours with [90Y-DOTATATE and tandem 90Y/177 Lu-DOTATATE: which is a better therapy option?” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 10, pp. 1788–1797, 2011.

[70] A. Sainz-Esteban, V. Prasad, C. Schuchardt, C. Zachert, J. M. Carril, and R. P. Baum, “Comparison of sequential planar [177 Lu-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 3, pp. 501–511, 2012.

[71] R. Valkema, S. A. Pauwels, L. K. Kvols et al., “Long-term follow-up of renal function after peptide receptor radiation therapy with [90Y-DOTA,Tyr3]octreotide and [177 Lu-DOTA,Tyr2]octreotate,” Journal of Nuclear Medicine, supplement 1, pp. 83S–91S, 2005.

[72] K. Öberg, L. Kvisl, M. Caplin et al., “Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system,” Annals of Oncology, vol. 15, no. 6, pp. 966–973, 2004.

[73] H. Zhang, M. A. Moroz, I. Serganova et al., “Imaging expression of the human somatostatin receptor subtype-2 reporter gene with [68 Ga-DOTATOC,” Journal of Nuclear Medicine, vol. 52, no. 1, pp. 123–131, 2011.

[74] M. Cremonesi, M. Ferrari, S. Zoboli et al., “Biokinetics and dosimetry in patients administered with [111 In-DOTA-Tyr3]octreotide: implications for internal radiotherapy with [90Y-DOTATOC,” European Journal of Nuclear Medicine, vol. 26, no. 8, pp. 877–886, 1999.

[75] D. Pach, A. Sowa-Staszczak, J. Kunikowska et al., “Repeated cycles of peptide receptor radionuclide therapy (PRRT)—results and side-effects of the radioisotope [90Y-DOTATATE, 177 Lu-DOTA TATE or 90Y/177 Lu-DOTA TATE therapy in patients with disseminated NET,” Radiotherapy and Oncology, vol. 102, no. 1, pp. 45–50, 2012.

[76] D. J. Kwekkeboom, B. L. Kam, M. Van Essen et al., “Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors,” Endocrine-Related Cancer, vol. 17, no. 1, pp. R53–R73, 2010.

[77] K. R. Zinn and T. R. Chaudhuri, “The type 2 human somatostatin receptor as a platform for reporter gene imaging,” European Journal of Nuclear Medicine, vol. 29, no. 3, pp. 388–399, 2002.

[78] B. E. Rogers, J. J. Parry, R. Andrews, P. Cordopatis, B. A. Nock, and T. Maina, “MicroPET imaging of gene transfer with a somatostatin receptor-based reporter gene and 94mTc-DTPA-demonate I,” Journal of Nuclear Medicine, vol. 46, no. 11, pp. 1889–1897, 2005.

[79] C. Orlando, C. C. Raggi, L. Bagnoni, R. Sestini, G. La Cava et al., “Somatostatin receptor type 2 gene expression in neuroblastoma, measured by competitive RT-PCR—is related to patient survival and to somatostatin receptor imaging by indium-111-pentetreotide,” Medical and Pediatric Oncology, vol. 36, pp. 224–226, 2001.

[80] V. Briganti, R. Sestini, C. Orlando et al., “Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors,” Clinical Cancer Research, vol. 3, no. 12, pp. 2385–2391, 1997.

[81] G. Cotugno, M. Aurilio, P. Annunziata et al., “Noninvasive repetitive imaging of somatostatin receptor 2 gene transfer with positron emission tomography,” Human Gene Therapy, vol. 22, no. 2, pp. 189–196, 2011.

[82] V. Kundra, F. Mannting, A. G. Jones, and A. I. Kassis, “Noninvasive monitoring of somatostatin receptor type 2 chimeric gene
transfer,” *Journal of Nuclear Medicine*, vol. 43, no. 3, pp. 406–412, 2002.

[83] K. R. Zinn, D. J. Buchsbaum, T. R. Chaudhuri, J. M. Mountz, W. E. Grizzle, and B. E. Rogers, “Noninvasive monitoring of gene transfer using a reporter receptor imaged with a high-affinity peptide radiolabeled with 99mTc or 188Re,” *Journal of Nuclear Medicine*, vol. 41, no. 5, pp. 887–895, 2000.

[84] D. J. Buchsbaum, T. R. Chaudhuri, M. Yamamoto, and K. R. Zinn, “Gene expression imaging with radiolabeled peptides,” *Annals of Nuclear Medicine*, vol. 18, no. 4, pp. 275–283, 2004.

[85] T. R. Chaudhuri, B. E. Rogers, D. J. Buchsbaum, J. M. Mountz, and K. R. Zinn, “A noninvasive reporter system to image adeno-viral-mediated gene transfer to ovarian cancer xenografts,” *Gynecologic Oncology*, vol. 83, no. 2, pp. 432–438, 2001.

[86] J. J. M. Teunissen, D. J. Kwekkeboom, R. Valkema, and E. P. Krenning, “Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours,” *Endocrine-Related Cancer*, vol. 18, supplement 1, pp. S27–S51, 2011.

[87] T. Belhocine, J. Foidart, P. Rigo et al., “Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67,” *Nuclear Medicine Communications*, vol. 23, no. 8, pp. 727–734, 2002.

[88] A. Al-Ibraheem, R. A. Bundschuh, J. Notni et al., “Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours?” *European Journal of Nuclear Medicine and Molecular Imaging*, vol. 38, no. 11, pp. 2005–2013, 2011.

[89] H. Orlefors, A. Sundin, U. Garske et al., “Whole-body 11C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography,” *Journal of Clinical Endocrinology and Metabolism*, vol. 90, no. 6, pp. 3392–3400, 2005.

[90] H. Rajekar, K. Bogammana, and R. S. Stubbs, “Selective internal radiation therapy for gastrointestinal neuroendocrine tumour liver metastases: a new and effective modality for treatment,” *International Journal of Hepatology*, vol. 2011, Article ID 404916, 7 pages, 2011.